 |
|
|
| |
Cobicistat versus Ritonavir as Pharmacoenhancers in Combination with Atazanavir Plus Tenofovir DF/Emtricitabine: Phase 3 Randomized, Double Blind,
Active-Controlled Trial, Week 48 Results
|
| |
| |
Reported by Jules Levin
XIX International AIDS Conference
July 24, 2012
Joel Gallant1, Ellen Koenig2, Jaime Andrade-Villanueva3, Ploenchan Chetchotisakd4, Edwin DeJesus5, Francisco Antunes6, Keikawus Arasteh7, Graeme Moyle8, Giuliano Rizzardini9, Jan Fehr10, YaPei Liu11, Lijie Zhong11, Christian Callebaut11, Srini Ramanathan11, Javier Szwarcberg11, Martin Rhee11, Andrew Cheng11
1Johns Hopkins University School of Medicine, Baltimore, US; 2Instituto Dominicano de Estudios Virologicos -IDEV-, Santo Domingo, Dominican Republic; 3Hospital Civil, Guadalajara, Mexico; 4Khon Kaen University, Muang District, Thailand; 5Orlando Immunology Center, Orlando, US; 6Hospital de Santa Maria, Lisboa, Portugal; 7EPIMED / Vivantes Auguste-Viktoria-Klinikum,
Berlin, Germany; 8Chelsea & Westminster Hospital, London, United Kingdom; 9Ospedale Luigi Sacco, Milano, Italy; 10University Hospital Zurich, Zurich, Switzerland; 11Gilead Sciences, Inc., Foster City, US
|
| |
|
|
|
|
|
